SCHEMBL23703360

SCHEMBL23703360

FC(F)(F)c1csc(NC2CCNC2)n1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ IDH2 P48735 2/20 0.45
▸ KCNH2 Q12809 1/20 0.44
▸ PRKCI P41743 10/20 0.42
▸ PIK3CA P42336 1/20 0.41
▸ IDH1 O75874 1/20 0.39
▸ CHEK1 O14757 1/20 0.38
▸ CHEK2 O96017 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ PLAT P00750 1/20 0.37
▸ HDAC4 P56524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23703358 1.00 IDH2 (0.45) IDH2KCNH2PRKCIPIK3CAIDH1
SCHEMBL3321777 0.91 MAPK1 (0.46) IDH2KCNH2PIK3CAIDH1MAPK1
SCHEMBL25140729 0.79 KCNH2 (0.52) IDH2KCNH2PRKCIPIK3CACHEK1
SCHEMBL26775804 0.78 PRKCI (0.44) PRKCIMAPK1
SCHEMBL13326581 0.78 PRKCI (0.44) PRKCIMAPK1
SCHEMBL30478386 0.72 PIK3CA (0.49) IDH2KCNH2PIK3CACHEK1CHEK2
SCHEMBL13334977 0.71 BAZ2A (0.43) KCNH2CHEK1MAPK1
SCHEMBL12526259 0.70 IDH2 (0.50) IDH2PIK3CAIDH1CHEK1MAPK1
SCHEMBL22895360 0.70 PIK3CA (0.47) IDH2PIK3CACHEK1MAPK1
SCHEMBL974801 0.69 CHRM2 (0.44) PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435061-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2025-10-07 — — US disclosed
EP-4574822-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2025-06-25 — — EP disclosed
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 — — CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 — — US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 — — US disclosed
EP-4096661-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2022-12-07 — — EP disclosed
CN-115335050-A Compounds and compositions for treating skin conditions 卡玛瑞制药有限公司 2022-11-11 — — CN disclosed
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2022-10-20 — — US disclosed
WO-2021154966-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2021-08-05 — — WO disclosed
WO-2021154966-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435061-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback